Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Frexalimab versus tacrolimus in adult first kidney transplant recipients
NL-OMON61253Not yet recruiting
- Sponsor
- Sanofi
- Start
- Apr 2026
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised trial in kidney allograft rejection and kidney transplant comparing Frexalimab arm with Tacrolimus arm (2 arms). Primary endpoint: Composite efficacy failure rate by 1 year post kidney transplantation. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
frexalimabtacrolimus
03
Conditions
kidney allograft rejectionkidney transplant
Beyond the preview
Go deeper on NL-OMON61253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61253.